



\$350 Million
Follow-On Offering



Joint Bookrunner
September 2023

Leerink Partners Serves as Joint Bookrunner for Crinetics Pharmaceuticals' (Nasdaq: CRNX) \$350 Million Upsized Follow-On Offering

Key Transaction Highlights

- Launched on September 11th post-close and priced on September 12th post-close
- The offering followed the September 10th release of positive topline data from PATHFNDR-1, Crinetics' first phase 3 trial of paltusotine in patients with acromegaly, leading to a one-day stock price reaction of 63.3%
- Well oversubscribed from both new and existing investors
- Base deal was upsized from \$250 million to \$350 million.
- Consisted of 11,441,648 shares at a price of \$30.59 per share, representing the last sale price and a 17.3% premium to launch.
- Crinetics intends to use the net proceeds from this offering to fund the development of paltusotine, CRN04894 and other research and development programs, and for working capital and general corporate purposes.
- This is Leerink Partners' 6th bookrun equity offering for Crinetics and 39th bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111